reports
Idorsia and Viatris enter into a significant global research and devel...
Idorsia and Viatris enter into a significant global research and development collaboration Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration ...
Idorsia and Viatris enter into a significant global research and devel...
Idorsia and Viatris enter into a significant global research and development collaboration Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.Viatris and Idorsia will both contribute to the development costs for both programs.Includes future optionality to expand collaboration ...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023. Patients with hypertension can often successfully control their blood p...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023 Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “” by George Bakris, MD, at the American Society of Nephrology (ASN) Kidney Week 2023. Patients with hypertension can often successfully control their blood p...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023 Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in patients with resistant hypertension – results from ...
New Phase 3 data with aprocitentan for patients with resistant hyperte...
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the European Society of Hypertension Annual Meeting 2023 Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in patients with resistant hypertension – results from ...
On World Sleep Day Idorsia highlights the publication of a global stud...
On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep1-3; research on wider societal and indirect economic costs associated with CID have been limited to date1New report indicates annual lost productivity costs of $417 billion in GDP across working age populations in the countries of focus* and annual “hidden” intangible wellbeing losses of $239.5 billion1Reducing the impact of CID could re...
On World Sleep Day Idorsia highlights the publication of a global stud...
On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep1-3; research on wider societal and indirect economic costs associated with CID have been limited to date1New report indicates annual lost productivity costs of $417 billion in GDP across working age populations in the countries of focus* and annual “hidden” intangible wellbeing losses of $239.5 billion1Reducing the impact of CID could re...
Idorsia submits a New Drug Application to the US FDA for aprocitentan ...
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, nov...
Idorsia submits a New Drug Application to the US FDA for aprocitentan ...
Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – December 20, 2022 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for aprocitentan, Idorsia’s investigational, nov...
Long-term safety and tolerability results with daridorexant in patient...
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuationExploratory efficacy endpoints show sustained improvements in nighttime sleep variables and daytime functioning Allschwil, Switzerland – December 12, 2022Idorsia Ltd (SIX: IDIA) today announced the publication of “” in CNS Drugs1. The publication reports the...
Long-term safety and tolerability results with daridorexant in patient...
Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs Daridorexant, taken every night for up to 12 months, was well-tolerated with no signs of tolerance (loss of effect) or physical dependence, and no evidence of withdrawal or rebound insomnia upon treatment discontinuationExploratory efficacy endpoints show sustained improvements in nighttime sleep variables and daytime functioning Allschwil, Switzerland – December 12, 2022Idorsia Ltd (SIX: IDIA) today announced the publication of “” in CNS Drugs1. The publication reports the...
Idorsia Ltd: 1 director
A director at Idorsia Ltd bought 3,000 shares at 13.800CHF and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Idorsia gibt Finanzergebnisse für das erste Halbjahr 2022 bekannt – Ko...
Idorsia gibt Finanzergebnisse für das erste Halbjahr 2022 bekannt – Kommerzielle Phase erreicht Ad-hoc-Mitteilung gemäss Art. 53 KR Allschwil, Schweiz – 26. Juli 2022 Idorsia Ltd (SIX: IDIA) gab heute die Finanzergebnisse für das erste Halbjahr 2022 bekannt. Operative Highlights QUVIVIQ™ (Daridorexant) wurde im Mai 2022 in den USA eingeführt und entwickelt schon früh eine positive Dynamik im Markt für Insomnie. Der Nettoumsatz lag im ersten Halbjahr 2022 bei CHF 0,4 Millionen.PIVLAZ™ (Clazosentan) wurde im April 2022 in Japan eingeführt und konnte sich dabei starker Unterstützung durch ...
Idorsia announces financial results for the first half 2022 – reachin...
Idorsia announces financial results for the first half 2022 – reaching commercial stage Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 26, 2022 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2022. Commercial highlights QUVIVIQ™ (daridorexant) was launched in the US in May 2022 and is building positive early momentum in the insomnia market. Net sales in the first half of 2022 were CHF 0.4 millionPIVLAZ™ (clazosentan) was launched in Japan in April 2022 with strong support from neurosurgeons treating aSAH patients. Net sales ...
Positive Phase 3 study with aprocitentan demonstrates significant anti...
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension Ad hoc announcement pursuant to Art. 53 LR Aprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concernsPrimary and key secondary endpoints were met with statistical significance and clinically meaningful results – the effect was consistent across multiple endpoints and methodologies of blood pressure monitoringIdors...
Positive Phase 3 study with aprocitentan demonstrates significant anti...
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension Ad hoc announcement pursuant to Art. 53 LR Aprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concernsPrimary and key secondary endpoints were met with statistical significance and clinically meaningful results – the effect was consistent across multiple endpoints and methodologies of blood pressure monitoringIdors...
PIVLAZ (clazosentan) – Idorsia’s first commercial product – now availa...
PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan In Japan, PIVLAZ™ (clazosentan) 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.With the positive listing decision, Japan’s National Health Insurance system has recognized that the clinical efficacy demonstrated with PIVLAZ fulfills an important medical need for patients.PIVLAZ is now available to physicians to start treating patients in Japan. Allschwil,...
PIVLAZ (clazosentan) – Idorsia’s first commercial product – now availa...
PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan In Japan, PIVLAZ™ (clazosentan) 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.With the positive listing decision, Japan’s National Health Insurance system has recognized that the clinical efficacy demonstrated with PIVLAZ fulfills an important medical need for patients.PIVLAZ is now available to physicians to start treating patients in Japan. Allschwil,...
IDORSIA LIMITED sees a downgrade to Slightly Negative on account of le...
The independent financial analyst theScreener just lowered the general evaluation of IDORSIA LIMITED (CH), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 18, 2022, the closing price was CHF 19.0...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.